Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Novel peptide

A technology of derivatives and compositions, applied in the field of new peptides or their derivatives or their salts, can solve the unknown problem of combining angiotensin-converting enzyme fibroblasts and collagen adhesion promotion activities to restore tension and elasticity , Solve beauty problems, improve wrinkles and sagging effects

Inactive Publication Date: 2013-12-11
ROHTO PHARM CO LTD
View PDF7 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

Furthermore, no material having both angiotensin-converting enzyme inhibitory activity and adhesion-promoting activity between fibroblasts and collagen has been known so far.

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Novel peptide
  • Novel peptide
  • Novel peptide

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0087] Embodiment 1: the preparation of peptide

[0088] 1-1. DLDVF (Asp-Leu-Asp-Val-Phe) peptide:

[0089] (1) Synthesis of peptides:

[0090] The title peptide was synthesized by a solid-phase synthesis method using the Fmoc method using an automatic peptide synthesizer (manufactured by Shimadzu Corporation: PSSM8). The specific procedure is as follows: First, after the C-terminal of Fmoc-Phe(1-Trt)-OH is bound to the resin for solid-phase synthesis, the protective group (Fmoc) is removed by piperidine treatment, and then the resin is neutralized. · After washing, introduce Fmoc-Val-OH into the N-terminus of Phe. Next, the protective group (Fmoc) was removed by piperidine treatment, and after neutralizing and washing the resin again, Fmoc-Asp(OtBu)-OH was introduced into the N-terminal of Val. Next, the protective group (Fmoc) was removed by piperidine treatment, and after neutralizing and washing the resin again, Fmoc-Leu-OH was introduced into the N-terminal of Asp. N...

Embodiment 2

[0103] Example 2: Determination of angiotensin-converting enzyme inhibitory activity

[0104] The angiotensin-converting enzyme inhibitory activity was measured using the various peptides prepared in Example 1 above.

[0105] Specifically, test solutions were prepared so that the concentration of each peptide was 1 mg / mL, and 1-fold, 10-fold, 100-fold, and 1000-fold dilutions were used to measure angiotensin-converting enzyme inhibitory activity. The angiotensin-converting enzyme inhibitory activity was evaluated by using the ACE Kit-WST kit (manufactured by Dojin Chemical Research Institute) to detect 3-hydroxybutyryl-Gly-Gly-Gly (3HB-GGG ), and measure the absorbance at 450 nm with a microplate reader. The ACE Kit-WST kit was used according to the attached protocol. The results are shown below.

[0106] [Table 1]

[0107] peptide IC50(mg / mL) IC50(μM)

[0108] DLDV 0.4472 725.2 RDLDV 0.3275 428.7 RDLDVF 0.3018 395.1

[01...

Embodiment 3

[0110] Example 3: Evaluation of Fibroblast Adhesion to Collagen Coatings

[0111] The effect of promoting adhesion of fibroblasts to the collagen coating was evaluated using various peptides prepared in Example 1 above.

[0112] Specifically, first, 2 × 10 4 Fibroblasts (クラボウ: KF-4009) from human normal skin were inoculated at a concentration of cells / well. Next, 200 μl of Dulbecco’s modified Eagle’s medium (D-MEM; FCS10%·AB1%) diluted so that the concentration of each peptide was 5 μg / ml was added to each well. % carbon dioxide and 95% air environment for 20 hours of cultivation. On the other hand, cells to which 200 μl of D-MEM medium to which no peptide was added were prepared as a control. After 4 hours from the start of the culture, the supernatant of each well was washed with PBS, and the remaining amount of collagen coating adhered to and not washed was measured in each well using the Cell Counting Kit-8 kit (manufactured by Dojin Chemical Research Institute of Co., ...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The purpose of the present invention is to provide a novel substance which has an activity of inhibiting an angiotensin-converting enzyme and / or an activity of promoting the adhesion between a fibroblast and collagen. A peptide comprising an amino acid sequence represented by formula (I): Xaa1-Asp-Leu-Asp-Val-Xaa2 (SEQ ID NO:1) [wherein Xaa1 and Xaa2 may be present or absent and, if present, independently represent an arbitrary amino acid residue], a derivative of the peptide, or a salt of the peptide or the derivative.

Description

technical field [0001] The present invention relates to a novel peptide having a specific amino acid sequence or a derivative thereof or a salt thereof. The novel peptides of the present invention or their derivatives or their salts can be used advantageously because they inhibit the activity of angiotensin-converting enzyme and also promote the adhesion between cells and collagen. Background technique [0002] Angiotensin-converting enzyme inhibitors are generally used widely for the treatment of hypertension and chronic heart failure. Angiotensin-converting enzyme inhibitors act on both the renin-angiotensin system of the pressor system and the kallikrein-kinin system of the depressor system in the living body, and exert the antihypertensive effect by dilating blood vessels, etc. Aspects are well known. Furthermore, it is also known that angiotensin-converting enzyme inhibitors have the effect of simultaneously reducing cardiac preload and afterload and improving cardiov...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
IPC IPC(8): C07K7/06A61K8/64A61K38/00A61P9/10A61P9/12A61P17/00A61P43/00A61Q19/00C07K5/113C07K7/14A61K38/08
CPCC07K5/0806C07K5/0808C07K5/1021C07K7/06A61K38/08A61K8/64A61Q19/08A61P17/00A61P43/00A61P9/10A61P9/12
Inventor 阿部正通熊泽益德松本康助
Owner ROHTO PHARM CO LTD
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com